R&D JP Morgan 2024 – Katherine Stueland Diagnostics can be a neglected part of the treatment paradigm, but it’s hugely important for connecting patients with the right treatments.
News ASH: Blenrep ups survival by 42% in multiple myeloma trial GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
